Fig. 6.

LINC00930 promotes NPC progression via PFKFB3. a and b Cell viability and colony formation was assessed after transfection of the PFKFB3 siRNA in LINC00930-overexpressing 6-10B and CNE1 cells. c The ECAR was measured and analyzed after transfection of the the PFKFB3 siRNA in LINC00930-expressing CNE1 cells. d and e Intracellular F-2,6-BP level and lactate level were assayed after transfection of the PFKFB3 siRNA in LINC00930-expressing CNE1 cells. f and g Cell viability and colony formation was assessed after treatment with PFKFB3 inhibitor PFK15 in LINC00930-overexpressing 6-10B and CNE1 cells. h The ECAR was measured and analyzed after treatment with PFKFB3 inhibitor PFK15 in LINC00930-overexpressing CNE1 cells. i and j Intracellular F-2,6-BP level and lactate level were detected after treatment with PFKFB3 inhibitor PFK15 in LINC00930-overexpressing CNE1 cells. k Kaplan-Meier analysis of overall survival of patients in cohort 1, cohort 2, and TCGA HNSC cohort with low (low expression of both LINC00930 and PFKFB3), high (high expression of both LINC00930 and PFKFB3) or intermediate LINC00930/PFKFB3 expression (log-rank test, two-sided). The p-value in a & f was determined by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test, no adjustments were made for multiple comparisons. The p-value in b, c, d, e, g, h, i & j was determined by a two-tailed unpaired Student’s t test. * p < 0.05; ** p < 0.01; *** p < 0.001